{"id":"W4387361131","doi":"10.1210/jendso/bvad114.1890","title":"FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study","year":2023,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Ophthalmology and Eye Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Placebo; Tolerability; Stock options; Clinical trial; Clinical endpoint; Internal medicine; Antagonist; Receptor; Adverse effect; Pharmacology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001069804,0.0002308011,0.0006796521,0.0000856428,0.0001218265,0.000009818383,0.0002143839,0.00004646492,0.00005305761],"category_scores_gemma":[0.0005338381,0.0001205828,0.0003693251,0.0007355893,0.000251491,0.00008809292,0.00008296485,0.0004371522,0.000007057636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002262201,"about_ca_system_score_gemma":0.000532629,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003063611,"about_ca_topic_score_gemma":0.00000828843,"domain_scores_codex":[0.9975808,0.0005438285,0.0007978097,0.0002807474,0.0004670009,0.0003297811],"domain_scores_gemma":[0.9981369,0.0003233645,0.0004238973,0.0005259945,0.0003037613,0.000286019],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0842292,0.0121392,0.8994355,0.0000332772,0.0005558587,0.0002405076,0.001308937,0.0001017696,0.0004093509,5.193441e-7,0.001360624,0.0001852687],"study_design_scores_gemma":[0.03034103,0.03012919,0.935354,0.0001308908,0.0003653174,0.00002070215,0.002933946,0.00002088742,0.00008057204,0.000008930001,0.0004949761,0.0001195922],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950663,0.00005172786,0.000003428117,0.003483448,0.0002436713,0.001057138,0.00006138666,0.00001609391,0.00001683756],"genre_scores_gemma":[0.999143,0.00004132512,0.0001766252,0.000169601,0.0000744533,0.00001326298,0.00002012984,0.0000252527,0.0003363258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05388817,"threshold_uncertainty_score":0.4917223,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02023059721447011,"score_gpt":0.3860755338942498,"score_spread":0.3658449366797796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}